Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Grünig, E; Milger, K; Omlor, A; Florea, A; Egenlauf, B; Ladage, D; Skowasch, D; Pittrow, D; Harbaum, L; Halank, M; Tutarel, O; Csonka, PK; Harutyunova, S; Ulrich, S; Lange, TJ; Sonnweber, T; Hess, V; Kneidinger, N; Klose, H.
Treatment Algorithm of Pulmonary Arterial Hypertension
PNEUMOLOGIE. 2025; 79(10): 775-786. Doi: 10.1055/a-2625-4905
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Kneidinger Nikolaus; Milger-Kneidinger Katrin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Targeted therapy for pulmonary arterial hypertension has a positive impact on the symptoms and prognosis of the disease. Targeted and early combination therapy demonstrates greater improvements compared to monotherapy. For treatment decisions, assessing the mortality risk based on risk stratification and the presence of comorbidities is essential. A low-risk status is desirable, but does not always guarantee long-term clinically stable disease. Therefore, early and regular reevaluations should be performed to monitor treatment response, determining the therapeutic consequences for treatment adjustment. Novel agents and the discovery of new mechanisms of action have greatly expanded and improved treatment options, but require further evaluation in long-term studies. The definition of new treatment goals, such as achieving remission of PAH, should be critically discussed among the new therapeutic options and further evaluated through prospective studies [1].
Find related publications in this database (Keywords): pulmonary hypertension; therapy; right heart insufficiency; pulmonary hypertension; therapy; right heart insufficiency